Who is sponsoring NCT07039201?

NCT07039201 is sponsored by Zhejiang University.

What drugs are being tested in NCT07039201?

Interventions in NCT07039201: CG-102-12C.

What condition does NCT07039201 study?

NCT07039201 studies Advanced Hepatocellular Carcinoma (HCC).

Is NCT07039201 still recruiting?

NCT07039201 is currently recruiting now. Last updated 22 January 2026.

Last reviewed 2026-01-22 · How we verify

NCT07039201

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)

Recruiting now NA Last updated 22 January 2026

What this trial tests

NA trial testing CG-102-12C in Advanced Hepatocellular Carcinoma (HCC) in 12 participants. Currently enrolling.

Timeline

28 June 2025

Primary endpoint
31 March 2027

31 July 2027

Quick facts

Lead sponsor	Zhejiang University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	28 June 2025
Primary completion	31 March 2027
Estimated completion	31 July 2027
Sites	2 locations across China

Drugs / interventions tested

CG-102-12C — full drug profile →

Conditions studied

Advanced Hepatocellular Carcinoma (HCC) — all drugs for Advanced Hepatocellular Carcinoma (HCC) →

Sponsor

Zhejiang University

Who can join

Adults 18 to 75, any sex, with Advanced Hepatocellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-centre, single-arm, open-label, dose-escalation exploratory study with single-dose administration. Its objective is to evaluate the safety, tolerability, dose, anti-tumor efficacy, and pharmacokinetic characteristics of CG-102-12C in the participants with GPC3-positive advanced hepatocellular carcinoma who previously received adequate but uneffective systemic standard treatments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Hepatocellular Carcinoma (HCC)

Currently open trials in the same condition.

NCT07493044 — An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma · Phase 1 · recruiting
NCT07500220 — Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC · Phase 1, PHASE2 · recruiting
NCT07123545 — Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT06902389 — A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT06828380 — A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Ca · Phase 2 · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07039201 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 22 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07039201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing